Gene therapy for restenosis: Are we ready?

Circulation Research

Volumn 82, Issue 3, 1998, Pages 306-313

  DeYoung, Mary Beth ^a   Dichek, David A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

Adenovirus; Gene therapy; Restenosis

Indexed keywords

ADENOVIRUS; ARTERY WALL; CLONING VECTOR; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; PRIORITY JOURNAL; RESTENOSIS; REVIEW;

EID: 0032559625     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.3.306     Document Type: Review

References (115)

1. Strauss WE, Fortin T, Hartigan P, Folland ED, Parisi AF, Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators. A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy: outcomes of a randomized clinical trial. Circulation. 1995;92:1710-1719.
2. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981-993.
3. King SB III, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH, Alazraki NP, Guyton RA, Zhao X-Q. A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med. 1994;331:1044-1050.
4. The Bypass Angioplasry Rcvascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217-225.
5. Hamm CW, Reimers J, Ischinger T, Rupprecht H-J, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. N Engl J Med. 1994;331:1037-1043.
6. Califf RM. Restenosis: the cost to society. Am Heart J. 1995;130: 680-684.
7. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Dekan J, Morel M-A. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
8. Fischman DL, Leon MB, Bairn DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randonuzed comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331:496-501.
9. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
10. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Preti PAM, Repetto S, De Servi S, Varani E. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, double-blind STARC study. Circulation. 1994;90: 2710-2715.
11. Tardif J-C, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Mattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997; 337:365-372.
12. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990;249:1285-1288.
13. Chapman GD, Lim CS, Gammon RS, Gulp SC, Desper JS, Bauman RP, Swain JL, Stack RS. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res. 1992;71:27-33.
14. Flugelman MY, Jaklitsch MT, Newman KD, Casscells W, Bratthauer GL, Dichek DA. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation. 1992;85:1110-1117.
15. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res. 1993;73:797-807.
16. Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner JM. Percutaneous arterial gene transfer in a rabbit model: efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest. 1992;90:936-944.
17. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 1993;72:1132-1138.
18. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. IM vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994;91: 10732-10736.
19. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-784.
20. Leiden JM. Gene therapy - promise, pitfalls, and prognosis. N Engl J Med. 1995;333:871-873.
21. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med. 1988;318: 1734-1737.
22. Califf RM, Fortin DF, Frid DJ, Harlan WR III, Ohman EM, Bengtson JR, Nelson CL, Tcheng JE, Mark DB, Stack RS. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol. 1991;17:2B-13B.
23. Schwanz SM, Reidy MA, O'Brien ERM. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost. 1995;74:541-551.
24. Schwartz RS, Edwards WD, Huber KC, Antoniades LC, Bailey KR, Camrud AR, Jorgenson MA, Holmes RS Jr. Coronary restenosis: prospects for solution and new perspectives from a porcine model. Mayo Clin Proc. 1993;68:54-62.
25. Dangas G, Fuster V. Management of restenosis after coronary intervention. Am Heart J. 1996;132:428-436.
26. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
27. Herrman J-PR, Hermans WRM. Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail? Drugs. 1993;46(pt I):18-52.
28. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
29. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling, N Engl J Med. 1994;330:1431-1438.
30. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong SC, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43.
31. Andersen HR, Mseng M, Thorwest M, Falk E. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury: insights from a porcine coronary (re)stenosis model. Circulation. 1996;93:1716-1724.
32. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V, de Jaegere P, de Feyter PJ, Roelandt JR TC, Serruys PW. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol. 1995;75:772-777.
33. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci U S A. 1996; 93:11421-11425.
34. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase: a new catheter approach. Atherosclerosis. 1987;65:215-225.
35. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
36. Borrelli E, Heyman R, Hsi M, Evans RM. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci U S A. 1988;85: 7572-7576.
37. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system, Proc Natl Acad Sci U S A. 1992; 89:33-37.
38. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287.
39. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG. Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
40. Indolfi C, Awedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, Chiariello M. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;1:541-545.
41. O'Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM, Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 1993;73:223-231.
42. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirusmediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
43. Mann JM, Davies MJ. Vulnerable plaque: relation of characteristics to degree of stenosis in human coronary arteries. Circulation. 1996;94: 928-931.
44. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet. 1996;347:305-307.
45. Lafont A, Guerot C, Lemarchand P. Which gene for which restenosis? Lancet. 1995;346:1442-1443.
46. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
47. Sellke FW, Boyle EM Jr, Verrier ED. Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction. Ann Thorac Surg. 1996;62:1222-1228.
48. Abdellatif M, MacLellan WR, Schneider MD. p21 Ras as a governor of global gene expression. J Biol Chem. 1994;269:15423-15426.
49. Cavanaugh AH, Hempel WM, Taylor LJ, Rogalsky V, Todorov G, Rothblum LI. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature. 1995;374:177-180.
50. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
51. Flaherty D, Zengxuan N, Van Pelt N, Zoldhelyi P, Gerard RD, Collen D. Overexpression of human constitutive nitric oxide synthase gene reduces neointima formation in balloon-injured rat carotid arteries. Circulation. 1996;94(suppl I):I-590. Abstract.
52. White CR, Brock TA, Chang L-Y, Crapo J, Briscoe P, Ku D, Bradley WA, Gigantic SH, Gore J, Freeman BA, Tarpey MM. Superoxide and peroxynitrite in atherosclerosis, Proc Natl Acad Sci U S A. 1994;91: 1044-1048.
53. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial Superoxide anion production. J Clin Invest. 1993;91: 2546-2551.
54. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S. Peroxynithce modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 1993;330: 181-185.
55. Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996;75:77-85.
56. Beckman JS, Koppenol WH, Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol. 1996;271:CI424-C1437.
57. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh-ishi S, Steinbrecher UP, HeineckeJW. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem. 1997;272:1433-1436.
58. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579.
59. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
60. Nabel EG, Plautz G, Nabel GJ. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Prise Natl Acad Sci U S A. 1992;89:5157-5161.
61. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudemchild CC. Nabel GJ. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimai hyperplasia in vivo. J Clin Invest. 1993;91:1822-1829.
62. Nabel EG, Yang Z-Y, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ. Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature. 1993;362: 844-846.
63. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342-1344.
64. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation. 1993;88:2838-2848.
65. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviralmediated expression of recombinant hirudin reduces neointimal formation after arterial injury. Nat Med. 1996;2:293-298.
66. Simari RD, San H, Rekhter M, Ohno T, Gordon D, Nabel GJ, Nabel EG. Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest. 1996;98: 225-235.
67. McKay RG, Fram DB, Hirst JA, Kiernan FJ, Primiano CA, Rinaldi MJ, Azrin MA, Mitchel JF, Waters DD. Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch™ catheter. Cathet Cardiovasc Diagn. 1994;33: 181-188.
68. Riessen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM. Arterial gene transfer using pure DNA applied directly to a hydrogelcoated angioplasty balloon. Hum Gene Ther. 1993;4:749-758.
69. Lambert CR, Leone JE, Rowland SM. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis. 1993;4:469-475.
70. Willard JE, Landau C, Glamann DB, Burns D, Jessen ME, Pirwitz MJ, Gerard, RD, Meidell, RS. Genetic modification of the vessel wall: comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus, Circulation. 1994;89:2190-2197.
71. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci U S A. 1990;87:4600-4604.
72. Lynch CM, Clowes MM, Osborne WRA, Clowes AW, Miller AD. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. Prof Natl Acad Sci U S A. 1992;89:1138-1142.
73. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J. Rossow S, Rosenfield K, Weir L, Brogi E, Schainfeld R. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease, Circulation. 1995;91:2687-2692.
74. Takeshita S, Tsummi Y, Couffinahl T, Asahara T, Bauten C, Symes J, Ferrara N, Isner JM. Gene transfer of naked DNA encoding for three isofonns of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest. 1996:75:487-501.
75. 165 gene transfer. Circulation. 1996;94:3291-3302.
76. 165 in patient with iichaemic limb. Lancet. 1996;348:370-374.
77. Asahara T, Bauters C, Pastore C, Keamey M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91: 2793-2801.
78. Yonemitsu Y, Kaneda Y, Morishita R, Nakagawa K, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 1996;75:313-323.
79. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury, Circulation. 1996;94:1074-1082.
80. Schneider MD, French BA. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation. 1993;88:1937-1942.
81. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP, Roberts R, Raizner AE. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in nonnal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation. 1994;90:2402-2413.
82. Steg PG, Feldman LJ, Scoazec J-Y, Tahlil O, Barry JJ, Boulechfar S, Ragot T, Isner JM, Perricaudet M. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation. 1994;90:1648-1656.
83. Rome JJ, Shayani V, Newman KD, Farrell S, Lee SW, Virmani R, Dichek DA. Adenoviral vector-mediated gene transfer into sheep arteries using a double-balloon catheter. Hum Gene Ther. 1994;5:1249-1258.
84. Li Q, Kay MA, Finegold M, Stratford-Pemcaudet LD, Woo SLC. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther. 1993;4:403-409.
85. Yang Y, Ertl HCJ, Wilson JM. MHC class 1-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1994;1:433-442.
86. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-4411.
87. Simon RH, Engelhardt JF, Yang Y, Zepeda M, Weber-Pendleton S, Grossman M, Wilson JM. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Toxicity study. Hum Gene Ther. 1993;4:771-780.
88. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation, 1995;91:2407-2414.
89. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neoimimal hyperplasia. J Clin Invest. 1995;96:2955-2965.
90. Lafont A, Loirand G, Pacaud P, Vilde F, Lemarchand P, Escande D. Vasomotor dysfunction early after exposure of nonnal rabbit arteries to an adenoviral vector. Hum Gene Ther. 1997;8:1033-1040.
91. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 1997;99: 209-219.
92. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis. 1995;171: 1090-1096.
93. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science, 1991;251: 788-791.
94. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 1993; 13:197-204.
95. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCartyJ, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis, J Clin Invest. 1993;92:945-951.
96. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
97. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenovimses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994;91: 6196-6200.
98. Fisher KJ, Choi H, Burda J, Chen S-J, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996;217:11-22.
99. Kochanek S, Clemens PR, Mitani K, Chen H-H, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Prof Natl Acad Sci U S A. 1996;93:5731-5736.
100. Lieber A, He C-Y, Kirillova I, Kay MA. Recombinant adenovimses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol. 1996;70:8944-8960.
101. Chen H-H, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR, Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A. 1997;94:1645-1650.
102. Kay MA, Holterman A-X, Meuse L, Gown A, Ochs HD, Linsley PS, Wilson CB. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet. 1995;11:191-197.
103. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol. 1996;70:6370-6377.
104. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byme BJ. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A. 1996;93:14082-14087.
105. Gnatenko D, Arnold TE, Zolotukhin S, Nuovo GJ, Muzyczka N, Bahou WF. Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. J Investig Med. 1997;45:87-98.
106. Rolling F, Nong Z, Pisvin S, Collen D. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther. 1997;4:757-761.
107. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated virus vectors for vascular gene delivery. Cire Res. 1997; 80:497-505.
108. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270:475-480.
109. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994;6:335-341.
110. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993;4:39-69.
111. Levine GN, Chodos AP, Loscalzo J. Restenosis following coronary angioplasty: clinical presentations and therapeutic options. Clin Cardiol. 1995;18:693-703.
112. Lehmann KG, Maas AC, van Domburg R, de Feyter PJ, van den Brand M, Serruys PW. Repeat interventions as a long-term treatment strategy in the management of progressive coronary artery disease. J Am Coll Cardiol. 1996;27:1398-1405.
113. Rajasubramanian G, Meidell RS, Landau C, Dollar ML, Holt DB, Willard JE. Prager MD, Eberhart RC. Fabrication of resorbable microporous intravascular stems for gene therapy applications. ASAIO J. 1994; 40:M584-5S9.
114. Wu L, Tan B, Srinivasan A, Gambhir S, Phelps ME, Herschman HR, Berk Aj. Monitoring adenovirus-directed gene expression in cultured cells and living animals. Presented at The Institute for Genome Research, Genomic Science Series, Conference on Gene Therapy; May 9-12, 1996; TIGR Science Education Foundation: Rockville, Md. Abstract.
115. Brown MS, Goldstein JL, Havel RJ, Steinberg D. Gene therapy for cholesterol. Nat Genet. 1994;7:349-350.